Bio-Rad Laboratories, Inc. is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, its products advance the discovery process and improve healthcare. Bio-Rad's customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 7,800 employees worldwide. Bio-Rad had revenues exceeding $2.5 billion in 2020.
Company profile
Ticker
BIO, BIO.B
Exchange
Website
CEO
Norman Schwartz
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Agilent • Waters • Illumina • Avantor • Mettler-Toledo International • Bruker • Perkinelmer • Seer • Cue Health • Cytek BioSciences ...
Former names
BIO RAD LABORATORIES INC
SEC CIK
Corporate docs
Subsidiaries
Bio-Rad Laboratories Pty Ltd • Bio-Rad Laboratories NV • Research Specialties for Laboratories NV • Bio-Rad Laboratórios Brasil Ltda. • DiaMed Latino-América S.A. • Bio-Rad Laboratories (Canada) Limited • Bio-Rad Laboratories (Shanghai) Co., Ltd. • Bio-Rad (Shanghai) Life Science Research • Wuxi BioCanal Nano Technology Co. Ltd. • Bio-Rad Laboratories (Suzhou) Co. Ltd. ...
IRS number
941381833
BIO stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
23 Feb 23
10-K
2022 FY
Annual report
17 Feb 23
8-K
Bio-Rad Reports Fourth-Quarter and Full-Year 2022 Financial Results
16 Feb 23
8-K
Regulation FD Disclosure
10 Jan 23
UPLOAD
Letter from SEC
16 Dec 22
CORRESP
Correspondence with SEC
14 Dec 22
UPLOAD
Letter from SEC
2 Dec 22
8-K
Regulation FD Disclosure
8 Nov 22
10-Q
2022 Q3
Quarterly report
28 Oct 22
8-K
Bio-Rad Reports Third-Quarter 2022 Financial Results
27 Oct 22
Transcripts
BIO
Earnings call transcript
2022 Q4
16 Feb 23
BIO
Earnings call transcript
2022 Q3
28 Oct 22
BIO
Earnings call transcript
2022 Q2
29 Jul 22
BIO
Earnings call transcript
2022 Q1
29 Apr 22
BIO
Earnings call transcript
2021 Q4
11 Feb 22
BIO
Earnings call transcript
2021 Q3
29 Oct 21
BIO
Earnings call transcript
2021 Q2
30 Jul 21
BIO
Earnings call transcript
2021 Q1
30 Apr 21
BIO
Earnings call transcript
2020 Q4
12 Feb 21
BIO
Earnings call transcript
2020 Q3
30 Oct 20
Latest ownership filings
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 434.54 mm | 434.54 mm | 434.54 mm | 434.54 mm | 434.54 mm | 434.54 mm |
| Cash burn (monthly) | 27.90 mm | 3.05 mm | (no burn) | 392.02 mm | (no burn) | (no burn) |
| Cash used (since last report) | 81.62 mm | 8.92 mm | n/a | 1.15 bn | n/a | n/a |
| Cash remaining | 352.92 mm | 425.62 mm | n/a | -712.29 mm | n/a | n/a |
| Runway (months of cash) | 12.6 | 139.6 | n/a | -1.8 | n/a | n/a |
Institutional ownership, Q4 2022
77.7% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 458 |
| Opened positions | 58 |
| Closed positions | 71 |
| Increased positions | 204 |
| Reduced positions | 129 |
| 13F shares | Current |
|---|---|
| Total value | 7.91 tn |
| Total shares | 19.06 mm |
| Total puts | 149.40 k |
| Total calls | 103.50 k |
| Total put/call ratio | 1.4 |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 2.39 mm | $1.01 tn |
| BLK Blackrock | 1.58 mm | $665.38 bn |
| Veritas Asset Management | 1.15 mm | $484.53 bn |
| STT State Street | 947.78 k | $398.53 bn |
| Brown Advisory | 820.89 k | $345.17 bn |
| Alliancebernstein | 480.90 k | $202.21 bn |
| Geode Capital Management | 434.89 k | $182.96 bn |
| Ubs Global Asset Management Americas | 419.43 k | $176.36 bn |
| BAC Bank Of America | 408.80 k | $171.89 bn |
| Westfield Capital Management | 389.50 k | $163.78 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 8 Mar 23 | Timothy S Ernst | Bio-Rad A Common Stock | Sell | Dispose S | No | No | 486.89 | 746 | 363.22 k | 2,671.364 |
| 8 Mar 23 | Timothy S Ernst | Bio-Rad A Common Stock | Sell | Dispose S | No | No | 486.08 | 1,000 | 486.08 k | 3,417.364 |
| 8 Mar 23 | Timothy S Ernst | Bio-Rad A Common Stock | Option exercise | Acquire M | No | No | 215.98 | 150 | 32.40 k | 4,417.364 |
| 8 Mar 23 | Timothy S Ernst | Bio-Rad A Common Stock | Option exercise | Acquire M | No | No | 159.32 | 850 | 135.42 k | 4,267.364 |
| 8 Mar 23 | Timothy S Ernst | NQSO Bio-Rad A Common Stock | Option exercise | Dispose M | No | No | 215.98 | 150 | 32.40 k | 2,350 |
| 8 Mar 23 | Timothy S Ernst | NQSO Bio-Rad A Common Stock | Option exercise | Dispose M | No | No | 159.32 | 850 | 135.42 k | 0 |
| 10 Feb 23 | Ajit Ramalingam | RSU Bio-Rad A Common Stock | Grant | Acquire A | No | No | 0 | 644 | 0.00 | 644 |
| 16 Dec 22 | Dara Wright | Bio-Rad A Common Stock | Payment of exercise | Dispose F | No | No | 407.98 | 226 | 92.20 k | 1,761.915 |
| 16 Dec 22 | Dara Wright | Bio-Rad A Common Stock | Option exercise | Acquire M | No | No | 0 | 502 | 0.00 | 1,987.915 |
| 16 Dec 22 | Dara Wright | RSU Bio-Rad A Common Stock | Option exercise | Dispose M | No | No | 0 | 502 | 0.00 | 1,005 |
News
Golden Cross Appears Before Bio-Rad Laboratories Investors
10 Mar 23
RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $579
17 Feb 23
Credit Suisse Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $680
17 Feb 23
Bio-Rad Laboratories Q4 EPS $3.31 Misses $3.45 Estimate, Sales $730.29M Miss $742.25M Estimate
16 Feb 23
Earnings Scheduled For February 16, 2023
16 Feb 23
Press releases
Resolve Biosciences Announces Appointment of John Stark as Chief Executive Officer
15 Mar 23
Bio-Rad to Participate in Citi's 2023 Healthcare Services, MedTech, Tools & HCIT Conference
17 Feb 23
Bio-Rad Reports Fourth-Quarter and Full-Year 2022 Financial Results
16 Feb 23
Element Biosciences and Bio-Rad Partner to Deliver Seamless RNA Sequencing Workflow Between Element's AVITI™ System and Bio-Rad's SEQuoia™ Express and SEQuoia™ Complete Stranded RNA Library Prep Kits
8 Feb 23
Cytek® Biosciences Partners with Bio-Rad to Expand Reagent Portfolios
7 Feb 23